Graticule Asia Macro Advisors LLC Adaptimmune Therapeutics PLC Transaction History

Graticule Asia Macro Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $1.34 Million - $2 Million	-346,500 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $660,441 - $920,574	-134,784 Reduced 28.01%	346,500 $1.84 Million
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $1.19 Million - $2.74 Million	297,804 Added 162.31%	481,284 $2.59 Million
Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $1.41 Million - $1.98 Million	183,480 New	183,480 $1.46 Million
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $695,600 - $2.62 Million	-185,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $868,350 - $1.42 Million	105,000 Added 131.25%	185,000 $2.51 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $3.51 Million - $4.62 Million	-336,457 Reduced 80.79%	80,000 $950,000
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $1.65 Million - $2.68 Million	-232,188 Reduced 35.8%	416,457 $4.68 Million
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $1.69 Million - $2.21 Million	252,821 Added 63.87%	648,645 $4.33 Million
Q3 2017 Nov 13, 2017	BUY	$4.93 - $8.93 $1.95 Million - $3.53 Million	395,824	395,824 $3.24 Million

116M

10.3K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $8.17M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Graticule Asia Macro Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Graticule Asia Macro Advisors LLC with notifications on news.